U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C27H29N3O2.ClH
Molecular Weight 463.999
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOZAVAPTAN HYDROCHLORIDE

SMILES

Cl.CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=CC=CC=C3C)C=C2)C4=C1C=CC=C4

InChI

InChIKey=MOROBKPIULFQDC-UHFFFAOYSA-N
InChI=1S/C27H29N3O2.ClH/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30;/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C27H29N3O2
Molecular Weight 427.5381
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800001739 http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=33180

Mozavaptan hydrochloride was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on July 26, 2006. It was developed and marketed as Physuline® by Otsuka in Japan. Mozavaptan hydrochloride is a vasopressin receptor antagonist. It is indicated for the treatment of hyponatremia due to excessive fluid retention when restriction of fluid intake is ineffective. Physuline® is available as film-coated tablet for oral use, containing 30 mg of Mozavaptan hydrochloride. The recommended dose is one tablet (30 mg) once daily after a meal.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.2 µM [IC50]
14.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PHYSULINE

Approved Use

PHYSULINE is used for the treatment of hyponatremia due to excessive fluid retention when restriction of fluid intake is ineffective.

Launch Date

2006
PubMed

PubMed

TitleDatePubMed
Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.
1992 Apr
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
1997 Oct
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
1998 Dec
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
1998 Dec
Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor.
1998 Nov 6
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
2000 Oct
Vasopressin V(1) receptor-mediated activation of central sympatho-adrenomedullary outflow in rats.
2002 Dec 13
Gateways to clinical trials.
2003 Jun
Ameliorative effect of NC-1900, a new AVP4-9 analog, through vasopressin V1A receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze.
2003 Mar
Prevention of hypoxic brain oedema by the administration of vasopressin receptor antagonist OPC-31260.
2008
Inhibitory effect of vasopressin receptor antagonist OPC-31260 on experimental brain oedema induced by global cerebral ischaemia.
2008 Mar
[Vasopressin receptor antagonists: the vaptans].
2010 May
Patents

Sample Use Guides

The recommended dose is one tablet (30 mg) once daily after a meal.
Route of Administration: Oral
In Vitro Use Guide
Mozavaptan caused a concentration-dependent displacement of the selective AVP V2 receptor antagonist radioligand, [3H]desGly-NH2(9)[d(CH2)5, D-Ile2,Ile4]AVP from V2 receptors in rat kidney medulla membranes. The concentration of Mozavaptan that displaced 50% of specific AVP binding (IC50) was 20 +/- 2 nmol/l for renal V2 receptors.
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:50:38 GMT 2023
Edited
by admin
on Sat Dec 16 05:50:38 GMT 2023
Record UNII
F39AR1YW1O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOZAVAPTAN HYDROCHLORIDE
WHO-DD  
Common Name English
Mozavaptan hydrochloride [WHO-DD]
Common Name English
MOZAVAPTANE HYDROCHLORIDE
JAN  
Common Name English
MOZAVAPTANE HYDROCHLORIDE [JAN]
Common Name English
BENZAMIDE, N-(4-((5-(DIMETHYLAMINO)-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-1-YL)CARBONYL)PHENYL)-2-METHYL-, HYDROCHLORIDE (1:1)
Systematic Name English
BENZAMIDE, N-(4-((5-(DIMETHYLAMINO)-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-1-YL)CARBONYL)PHENYL)-2-METHYL-, MONOHYDROCHLORIDE, (±)-
Common Name English
MOZAVAPTAN HYDROCHLORIDE [MI]
Common Name English
N-(4-(((5RS)-5-(DIMETHYLAMINO)-2,3,4,5-TETRAHYDRO-1H-BENZO(B)AZEPIN-1-YL)CARBONYL(PHENYL)-2-METHYLBENZAMIDE MONOHYDROCHLORIDE
Common Name English
PHYSULINE
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C2180
Created by admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C132047
Created by admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
PRIMARY
PUBCHEM
636389
Created by admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
PRIMARY
EVMPD
SUB90651
Created by admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
PRIMARY
EPA CompTox
DTXSID90930125
Created by admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
PRIMARY
FDA UNII
F39AR1YW1O
Created by admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
PRIMARY
CAS
138470-70-9
Created by admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
PRIMARY
SMS_ID
100000141041
Created by admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
PRIMARY
MERCK INDEX
m11874
Created by admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY